Literature DB >> 2458256

A rapid method of epitope mapping. Application to the study of immunogenic domains and to the characterization of various forms of rabbit progesterone receptor.

F Lorenzo1, A Jolivet, H Loosfelt, M Thu vu Hai, S Brailly, M Perrot-Applanat, E Milgrom.   

Abstract

A method is described to map contiguous epitopes recognized by monoclonal antibodies in the case when the cDNA for a protein has been cloned. The cDNA is inserted into an expression vector allowing its acellular transcription, followed by the translation of the resulting messenger RNA. C-terminally truncated species of the protein are either generated by cutting the cDNA with restriction enzymes or arise spontaneously through stops occurring during translation of the mRNA. If necessary, progressive digestion by Bal31 of the cDNA can be used to produce an array of polypeptides having different C-terminal lengths. Immunoprecipitation then allows determination of the shortest protein recognized by the monoclonal antibody and thus to define its site of action. This method has been applied to the study of a group of selected monoclonal antibodies among the 59 that have been prepared against the rabbit progesterone receptor. Four immunogenic domains were identified lying between amino acids 1-60, 101-110, 295-325 and 370-396. There were no antibodies directed against the DNA-binding or the steroid-binding regions of the receptor. This is probably due to the high degree of amino acid sequence conservation in these domains, observed when comparing receptors from different species. The antibodies cross-reacting with highest affinity for the human receptor interact with the first immunogenic domain (amino acids 1-60). The 79-kDa form ('subunit A') of the receptor was shown to lack the two more N-terminally localized immunogenic domains (amino acids 1-60 and 101-110). The 65-kDa form lacked, in addition, the domain localized between amino acids 295 and 325. These two forms of the receptor thus correspond to deletions of the N-terminal part of the protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458256     DOI: 10.1111/j.1432-1033.1988.tb14250.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

1.  Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity.

Authors:  Larbi Amazit; Audrey Roseau; Junaid A Khan; Anne Chauchereau; Rakesh K Tyagi; Hugues Loosfelt; Philippe Leclerc; Marc Lombès; Anne Guiochon-Mantel
Journal:  Mol Endocrinol       Date:  2011-01-27

2.  Heterotetrameric structure of the human progesterone receptor.

Authors:  P Rehberger; M Rexin; U Gehring
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

3.  Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells.

Authors:  L Klein-Hitpass; A C Cato; D Henderson; G U Ryffel
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

4.  p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization.

Authors:  Junaid A Khan; Larbi Amazit; Catherine Bellance; Anne Guiochon-Mantel; Marc Lombès; Hugues Loosfelt
Journal:  Mol Endocrinol       Date:  2011-08-04

5.  Immunocytochemical study of progesterone receptor in human meningioma.

Authors:  M Perrot-Applanat; M T Groyer-Picard; M Kujas
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

6.  In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA.

Authors:  K Delabre; A Guiochon-Mantel; E Milgrom
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

7.  Nuclear localization signals also mediate the outward movement of proteins from the nucleus.

Authors:  A Guiochon-Mantel; K Delabre; P Lescop; E Milgrom
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

8.  Immunocytochemical staining of progesterone receptor in paraffin sections of human breast cancers.

Authors:  M Perrot-Applanat; M T Groyer-Picard; M T Vu Hai; C Pallud; F Spyratos; E Milgrom
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

9.  Novel monoclonal antibodies against human uterine progesterone receptor. Mapping of receptor immunogenic domains.

Authors:  M T Vu Hai; A Jolivet; V Ravet; F Lorenzo; M Perrot-Applanat; M Citerne; E Milgrom
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

10.  Nucleocytoplasmic shuttling of the progesterone receptor.

Authors:  A Guiochon-Mantel; P Lescop; S Christin-Maitre; H Loosfelt; M Perrot-Applanat; E Milgrom
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.